Fairvalue-Calculator Fairvalue-Calculator
EN DE

Korean Drug Co (014570) Fair Value & Analysis

Healthcare · KR · Market cap 36.1B KRW

Price3,200 KRW
Fair Value6,929 KRW
Upside+116.5%
Quality95/100
Evidence: High Range 5,241 KRW – 8,661 KRW

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Korean Drug Co (014570) currently trades at 3,200 KRW, while our model-based Fair Value estimate is 6,929 KRW — implying the stock looks roughly 116.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Korean Drug Co., Ltd. manufactures and sells medicines for treating various diseases in South Korea. The company offers Medicines for urinary tract disease, digestive system, circulatory system, psychonervous system, central nervous system, respiratory system, and skin and subcutaneous system; and antivirals, antibiotics, antifungals, antipyretic, analgesis, anti-inflammatory, and other products. Korean Drug Co., Ltd. was founded in 1980 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Eli Lilly and Company (LLY) -64% Johnson & Johnson, (JNJ) -96% AbbVie Inc (ABBV) -71% Roche Holding (ROGN) -96% Merck & Co (MRCK34) -81% AstraZeneca PLC (A1ZN34) -84%

Frequently asked questions

Is Korean Drug Co (014570) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 6,929 KRW versus a price of 3,200 KRW — about +117% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 014570?
Our 21-model fair value for Korean Drug Co is 6,929 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 3,200 KRW.
What is the quality score of 014570?
Korean Drug Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.